Document is current
Any future updates will be listed below
-
Authors
Arai, Yusuke
Takahashi, Hidenori
Inoda, Satoru
Sakamoto, Shinichi
Kawashima, Hidetoshi
Yanagi, Yasuo
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP21K16880)
- License Information
-
More Information
Article History
Received: 18 June 2024
Revised: 4 January 2025
Accepted: 9 January 2025
First Online: 18 January 2025
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Jichi Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: was obtained from all patients who participated in the study.
: All authors have no conflicts of interest in this study.
: Hidenori Takahashi: Lecturer’s fees from Novartis Pharmaceuticals, Bayer Yakuhin, Kowa Pharmaceutical, Senju Pharmaceutical, Alcon Pharmaceuticals, Santen Pharmaceutical, and Pfizer; grants from Alcon Pharmaceuticals, Senju Pharmaceuticals, and Bayer Yakuhin; consultant’s fee from Novartis Pharmaceuticals; patents pending; and founder of DeepEyeVision Inc.; all outside this work. Hidetoshi Kawashima: Lecturer’s fees from Kowa Pharmaceutical, Novartis Pharmaceuticals, and Santen Pharmaceutical, all outside this work. Yasuo Yanagi: Lecturer’s fees and grants from Santen Pharmaceutical, all outside this work; advisory board member for Bayer Healthcare AG; and consultant for Santen Pharmaceuticals.
